RIPK1 and psoriasis: In addition, two other RIPK1 antagonists such as GSK2982772 and GSK31450395 have been developed by GlaxoSmithKline (GSK); among them, GSK2982772 is currently being evaluated in phase IIa trials for rheumatoid arthritis (NCT02858492), ulcerative colitis (NCT02903966), and psoriasis (NCT02776033) [196,197], and GSK31450395 was withdrawn from phase I clinical trials because no negative effects were observed on solid tumors growth and metastasis [198].